KIMS Q2 : CONS NET PROFIT UP 5.6% AT ₹76 CR (YOY), UP 105.4% (QOQ)

• Revenue up 41.3% at ₹1,363 Cr (YoY), up 14.0% (QoQ). • Ebitda up 34.0% at ₹279 Cr (YoY); margins 20.5% vs 21.7% (YoY), 20.1% (QoQ). • Earnings per share up 8.5% at ₹1.8 (YoY); cash and cash equivalents ₹420 Cr as on 30 Sep 2026. • Caution: PBT includes gain on fair valuation of call option and statutory impact of new labor codes. Impact: Profit growth accompanied by revenue and Ebitda increase, while margins declined YoY and QoQ; PBT includes fair-value gain and labor-code impact.

Krishna Institute of Medical Sciences Limited

Open attachment

← Back to feed